Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
Tulisokibart Phase 2 Results Expected
Tulisokibart • Hidradenitis Suppurativa
Target Indication
Hidradenitis Suppurativa
Clinical Trial
Last updated: 12/13/2025
MRK
MERCK
Renal Cell Carcinoma
Mesothelioma
Psoriasis
Metastatic Esophageal Squamous Cell Carcinoma
Colorectal Neoplasms